首页> 外文期刊>Pediatric blood & cancer >Ophthalmic artery chemosurgery for the management of retinoblastoma in eyes with extensive (>50%) retinal detachment
【24h】

Ophthalmic artery chemosurgery for the management of retinoblastoma in eyes with extensive (>50%) retinal detachment

机译:眼动脉化学外科手术治疗视网膜脱离(> 50%)的视网膜母细胞瘤

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Superselective delivery of chemotherapy through the ophthalmic artery, i.e. ophthalmic artery chemosurgery, has been used for the treatment of advanced intraocular retinoblastoma. Herein, we evaluate the efficacy of ophthalmic artery chemosurgery for retinoblastoma associated with >50% retinal detachment. Procedure: Retrospective review of 37 eyes of 34 retinoblastoma patients who had extensive (>50%) bullous non-rhegmatogenous retinal detachments and received ophthalmic artery chemosurgery either as primary treatment or as "salvage" treatment after failed multi-cycle intravenous chemotherapy and/or external beam radiation (mean follow-up, 21 months). Data on patient and ocular survival, complications of ophthalmic artery chemosurgery treatments, time course of retinal reattachment, and serial electroretinograms (ERG) were collected. Results: A total of 134 ophthalmic artery chemosurgery injections were performed. All children survive. Five eyes (5/37; 14%) were enucleated for progression of disease. The Kaplan-Meier enucleation-free survival rate at 2 years was 87.9% (95% confidence interval, 76.5-99.3%). The retina reattached in 28 eyes (28/37; 76%) and the 30-Hz flicker ERGs improved by >25μV in seven eyes (7/37; 19%), remained stable (change<25μV) in 26 eyes (26/37; 70%), and decreased by >25μV in four eyes (4/37; 11%). The Kaplan-Meier retinal reattachment rate was 58% after 3 months and three ophthalmic artery chemosurgery infusions (95% confidence interval, 41.9-74.1%). Conclusions: Ophthalmic artery chemosurgery is effective in preventing enucleation, promoting retinal reattachment and preserving or improving retinal function in the majority of eyes with advanced retinoblastoma and >50% retinal detachment that would otherwise be considered for enucleation.
机译:背景:通过眼动脉超选择性递送化学疗法,即眼动脉化学外科手术,已经用于治疗晚期眼内视网膜母细胞瘤。在本文中,我们评估了眼动脉化疗对视网膜母细胞瘤与> 50%视网膜脱离相关的疗效。程序:回顾性分析34例视网膜视网膜母细胞瘤患者的37眼,这些患者具有广泛的(> 50%)大疱性非血源性视网膜脱离,并在多周期静脉化疗和/或失败后接受眼动脉化学手术作为主要治疗或“挽救”治疗外部束辐射(平均随访21个月)。收集有关患者和眼睛存活率,眼动脉化学手术治疗并发症,视网膜复位的时程以及连续视网膜电图(ERG)的数据。结果:共进行了134次眼动脉化疗手术注射。所有的孩子都能生存。摘除五只眼(5/37; 14%)的疾病进展。 2年时Kaplan-Meier无结石存活率为87.9%(95%置信区间为76.5-99.3%)。视网膜重新附着在28眼(28/37; 76%)中,七只眼(7/37; 19%)的30 Hz闪烁ERG改善>25μV,在26眼(26/26)保持稳定(变化<25μV) 37; 70%),并在四只眼中降低了>25μV(4/37; 11%)。 3个月和3次输注眼动脉化学手术后,Kaplan-Meier视网膜的再附着率为58%(95%置信区间,41.9-74.1%)。结论:眼动脉化学外科手术可有效预防大多数成年视网膜细胞母细胞瘤和> 50%视网膜脱离的眼睛摘除,摘除视网膜,促进视网膜重新附着并保持或改善视网膜功能,否则可考虑将其摘除。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号